drugset
drugset / Trial / NCT06680947

A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma

NCT06680947 ↗

Phase 2 Active not recruiting 225 enrolled Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study will assess the effcacy and safety of 610 as an adjunctive therapy in adult subjects with severe eosinophilic asthma.

Timeline

Start
2024-12-20
Primary completion
2027-02
Completion
2027-09

Drugs

EvaluationDrugModalityDoseRoute
Subject 610 Monoclonal antibody — Subcutaneous

Indications

asthma